COLLEGIUM PHARMACEUTICAL INC (COLL)

US19459J1043 - Common Stock

29.7  -0.74 (-2.43%)

After market: 30 +0.3 (+1.01%)

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (12/20/2024, 8:03:35 PM)

After market: 30 +0.3 (+1.01%)

29.7

-0.74 (-2.43%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%203.77%
Sales Q2Q%16.52%
CRS21.49
6 Month-6.25%
Overview
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-20 2025-02-20/amc
Ins Owners0.82%
Inst Owners126.05%
Market Cap957.83M
Shares32.25M
PE5.4
Fwd PE4.43
Dividend YieldN/A
Analysts80
Short Float %19.25%
Short Ratio14.42
IPO05-07 2015-05-07
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

COLL Daily chart

Company Profile

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 197 full-time employees. The company went IPO on 2015-05-07. The firm commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

Company Info

COLLEGIUM PHARMACEUTICAL INC

100 Technology Center Dr

Stoughton MASSACHUSETTS 02072

P: 17817133699

CEO: Joseph Ciaffoni

Employees: 197

Website: https://www.collegiumpharma.com/

COLL News

News Imagea month ago - Collegium Pharmaceutical, Inc.Collegium to Participate in Upcoming Investor Conferences
News Imagea month ago - Collegium Pharmaceutical, Inc.Collegium Reports Record Third Quarter 2024 Financial Results
News Imagea month ago - Collegium Pharmaceutical, Inc.Collegium Reports Record Third Quarter 2024 Financial Results

– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER...

News Imagea month ago - Collegium Pharmaceutical, Inc.Collegium Appoints Vikram Karnani as Chief Executive Officer

Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses

News Imagea month ago - Collegium Pharmaceutical, Inc.Collegium Appoints Vikram Karnani as Chief Executive Officer

Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses...

News Image2 months ago - Market News VideoCollegium Pharmaceutical is Now Oversold (COLL)

COLL Twits

Here you can normally see the latest stock twits on COLL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example